Subsquent Events	9 Months Ended
Sep. 30, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	24. Subsequent Events On October 15, 2014 the Board of AbbVie confirmed that it had withdrawn its recommendation of its offer for Shire as a result of the anticipated impact of the US Treasury Notice on the benefits that AbbVie expected from its offer. As AbbVie's offer was conditional on the approval of its stockholders, and given their Board's decision to change its recommendation and to advise AbbVie's stockholders to vote against the offer, there was no realistic prospect of satisfying this condition. Accordingly, Shire's Board agreed with AbbVie to terminate the cooperation agreement on October 20, 2014. The UK Takeover Panel has confirmed that the offer period has ended. The Company has entered into a termination agreement with AbbVie, pursuant to which AbbVie has paid the break fee due under the cooperation agreement of approximately $1.635 billion, which will be recorded as a credit to the Company's consolidated income statement in the fourth quarter of 2014. The Company is evaluating the associated tax impact.

Subsquent Events

9 Months Ended

Sep. 30, 2014

24. Subsequent Events

On October 15, 2014 the Board of AbbVie confirmed that it had withdrawn its recommendation of its offer for Shire as a result of the anticipated impact of the US Treasury Notice on the benefits that AbbVie expected from its offer. As AbbVie's offer was conditional on the approval of its stockholders, and given their Board's decision to change its recommendation and to advise AbbVie's stockholders to vote against the offer, there was no realistic prospect of satisfying this condition. Accordingly, Shire's Board agreed with AbbVie to terminate the cooperation agreement on October 20, 2014. The UK Takeover Panel has confirmed that the offer period has ended. The Company has entered into a termination agreement with AbbVie, pursuant to which AbbVie has paid the break fee due under the cooperation agreement of approximately $1.635 billion, which will be recorded as a credit to the Company's consolidated income statement in the fourth quarter of 2014. The Company is evaluating the associated tax impact.